Mouse Monoclonal Thrombin antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 7 publications. Immunogen corresponding to Native Full Length Protein corresponding to Human F2.
View Alternative Names
Prothrombin, Coagulation factor II, F2
- IHC-P
AbReview41773****
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Thrombin antibody [5G9] (AB17199)
ab17199 staining Thrombin in human liver tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde, permeabilized with 0.2% Triton X-100 in PBS and blocked with 5% milk for 30 minutes at room temperature; antigen retrieval was by heat mediation in Tris pH 9.0. Samples were incubated with primary antibody (1/100 in PBS) for 16 hours at 4°C. An undiluted Biotin-conjugated horse anti-mouse IgG polyclonal was used as the secondary antibody.
This image is courtesy of an Abreview submitted by Steffen Rickelt
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Thrombin antibody [5G9] (AB17199)
IHC image of Thrombin staining in human liver formalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab17199, 10μg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
- WB
Unknown
Western blot - Anti-Thrombin antibody [5G9] (AB17199)
Thrombin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
All lanes:
Western blot - Anti-Thrombin antibody [5G9] (ab17199) at 1 µg/mL
Lane 1:
Human liver tissue lysate - total protein (<a href='/en-us/products/unavailable/human-liver-tissue-lysate-total-protein-ab29889'>ab29889</a>) at 10 µg
Lane 2:
Human Plasma Total Protein Lysate at 10 µg
Lane 3:
Western blot - Hep G2 nuclear extract lysate (<a href='/en-us/products/tissue-lysates/hep-g2-nuclear-extract-lysate-ab14660'>ab14660</a>) at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Mouse IgG H&L (HRP) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-hrp-preadsorbed-ab97040'>ab97040</a>) at 1/5000 dilution
Predicted band size: 70 kDa
Observed band size: 40 kDa,75 kDa
true
Exposure time: 12min
- WB
CiteAb
Western blot - Anti-Thrombin antibody [5G9] (AB17199)
Thrombin western blot using anti-Thrombin antibody [5G9] ab17199. Publication image and figure legend from Tang, X., Zhang, Z., et al., 2020, Cell Res, PubMed 31811276.
ab17199 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab17199 please see the product overview.
Effects of both apo- and holo-transferrin on thrombin, FXIIa and antithrombin. a Potentiating effects of both apo- and holo-transferrin on thrombin. b, c Representative RP-HPLC analysis (b) and quantification (c) of fibrinopeptide A (FbpA) and fibrinopeptide B (FbpB) released from 5 mg of fibrinogen hydrolyzed by 0.1 NIH unit thrombin mixed with 0, 0.2, 1, or 5 μM apo-transferrin, respectively. d Potentiating effects of both apo- and holo-transferrin on FXIIa. e, f Representative western blot (e) and quantification analysis of kallikrein heavy chain (HC ~52 kDa) (f) released from 10 μg of prekallikrein (PK) hydrolyzed by 0.01 NIH unit FXIIa mixed with 0, 0.2, 1, or 5 μM apo-transferrin (lane 2–5), respectively. Blots of PK, FXIIa heavy chain (FXIIa HC), transferrin, and kallikrein light chain (LC ~36 and 33 kDa) are also shown. g–j Apo- and holo-transferrin block antithrombin (AT)'s inactivation effect on thrombin (g, h) and FXa (i, j). TAT : thrombin–AT complex. HSA : human serum albumin. Data represent mean ± SD of five independent experiments, *p < 0.05, **p < 0.01 by one-way ANOVA with Dunnett's post hoc test. N.S. : no significance; Tf : transferrin
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Thrombin modulates several physiological processes beyond clot formation. It serves as a signaling molecule interacting with protease-activated receptors (PARs) to influence cell functions including proliferation migration and apoptosis. Thrombin forms part of the prothrombinase complex comprised of prothrombin activated Factor X (Xa) and Factor V on phospholipid surfaces. This complex is critical for thrombin generation during the clotting cascade. Thrombin's activity extends to involvement in wound healing and inflammation regulation.
Pathways
Thrombin significantly participates in the coagulation and fibrinolytic pathways. It not only converts fibrinogen to fibrin in the coagulation pathway but also activates inhibitors like antithrombin which regulates thrombin and other protease activities. Thrombin's interaction with fibrinolysis where tPA and plasminogen are substrates integrates clot disintegration processes. Thrombin's connectivity with proteins such as Factor VII Protein C and antithrombin outlines its diverse role in maintaining hemostatic balance.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (7)
Recent publications for all applications. Explore the full list and refine your search
Molecular neurodegeneration 19:67 PubMed39380021
2024
Applications
Unspecified application
Species
Unspecified reactive species
Annals of medicine and surgery (2012) 86:850-855 PubMed38333285
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature biotechnology 40:1601-1609 PubMed35668324
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell chemical biology 28:1728-1739.e5 PubMed34352225
2021
Applications
Unspecified application
Species
Unspecified reactive species
International journal of oral and maxillofacial surgery 50:163-170 PubMed32536459
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cell research 30:119-132 PubMed31811276
2019
Applications
Unspecified application
Species
Unspecified reactive species
Cells 8: PubMed31394759
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com